Boston Bio Systems Ltd Stock Price Today (NSE: BOSTONBIO)
Fundamental Score
Boston Bio Systems Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Boston Bio Systems Ltd share price today is ₹7.49, up +0.00% on NSE/BSE as of 18 August 2026. Boston Bio Systems Ltd (BOSTONBIO) is a Small-cap company in the Healthcare Service Provider sector with a market capitalisation of ₹3.54 (Cr). The 52-week high for BOSTONBIO share price is ₹10.95 and the 52-week low is ₹5.13. The company has a Return on Equity (ROE) of -10.34% and a debt-to-equity ratio of 0.18.
Boston Bio Systems Ltd Share Price Chart — NSE/BSE Historical Performance
Boston Bio Systems Ltd share price chart: 45.16% return over the past month. 52-week high ₹10.95, 52-week low ₹5.13.
Boston Bio Systems Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹7.49 | ₹7.49 | ₹7.49 | ₹7.49 | 1.04K (Cr) | |
| ₹7.88 | ₹7.88 | ₹7.88 | ₹7.88 | 1.00K (Cr) | |
| ₹9.15 | ₹9.15 | ₹8.29 | ₹8.29 | 13.99K (Cr) | |
| ₹8.72 | ₹8.72 | ₹8.72 | ₹8.72 | 2.71K (Cr) | |
| ₹8.31 | ₹8.31 | ₹8.31 | ₹8.31 | 95.00 (Cr) | |
| ₹8.32 | ₹8.32 | ₹8.31 | ₹8.31 | 11.91K (Cr) | |
| ₹7.94 | ₹7.94 | ₹7.94 | ₹7.94 | 185.00 (Cr) | |
| ₹7.57 | ₹7.57 | ₹7.57 | ₹7.57 | 100.00 (Cr) | |
| ₹7.21 | ₹7.21 | ₹7.21 | ₹7.21 | 11.52K (Cr) | |
| ₹6.87 | ₹6.87 | ₹6.87 | ₹6.87 | 5.00K (Cr) |
Boston Bio Systems Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹7.49 | ₹7.49 | ₹7.49 | ₹7.49 | +0.00% | |
| ₹5.16 | ₹9.15 | ₹5.16 | ₹7.88 | +52.71% | |
| ₹7.35 | ₹7.35 | ₹5.13 | ₹5.15 | -29.93% | |
| ₹7.63 | ₹10.95 | ₹7.63 | ₹8.13 | +6.55% | |
| ₹7.30 | ₹7.99 | ₹6.36 | ₹7.27 | -0.41% | |
| ₹8.50 | ₹8.50 | ₹6.58 | ₹6.96 | -18.12% | |
| ₹8.45 | ₹9.52 | ₹7.32 | ₹8.50 | +0.59% | |
| ₹8.45 | ₹9.29 | ₹7.45 | ₹8.05 | -4.73% | |
| ₹9.25 | ₹9.25 | ₹8.39 | ₹8.88 | -4.00% |
AI Research Briefing
Powered by Gemini · 2026-08-01
A revenue-less micro-cap shell with 2.14% promoter skin-in-the-game and widening net losses.
WHAT'S HAPPENING NOW (last 2-4 weeks)
No major catalysts found after live search. Boston Bio Systems (renamed Boston Commerce Limited) scheduled an Extraordinary General Meeting for August 5, 2026, following a board meeting on July 7, 2026. Standalone net loss for the March 2026 quarter widened to ₹0.65 crore, while latest quarterly sales collapsed by 100.0% YoY, confirming a complete operational standstill.
CORE STORY (THE REAL GAME)
This is a micro-cap shell play undergoing administrative rebrand attempts rather than a functioning healthcare business. The pivot from share broking to medical equipment distribution has generated no commercial traction, leaving the ticker exposed to pure speculative flow.
- No major catalysts found after live search; latest quarter sales dropped 100% YoY.
- March 2026 standalone net loss widened to ₹0.65 crore.
- Upcoming August 5, 2026 EGM introduces corporate uncertainty without visible operational backing.
- Outcome of August 5, 2026 EGM regarding corporate restructure or capital raising.
- First commercial revenue realization in medical trading segment.
- Promoter equity infusion or strategic entry by new buyers.
- Severe micro-cap illiquidity risk with a market cap of only ₹3.54 Cr.
- Promoter holding diluted down to an alarming 2.14%.
- Latest quarter sales collapsed 100% YoY alongside a net loss of ₹0.65 crore.
Promoters hold a negligible 2.14% (0.0% delta); FII presence is 0.0%; DII stands at 1.7% (+1.7% delta).
Domestic healthcare demand is robust, but micro-distributors lacking scale or capital face complete disintermediation.
No major news found after live search.
Weak; 5-year total Free Cash Flow stands at a meager ₹0.53 Cr with negative ROE at -10.34%.
High risk of continued value erosion without a fundamental business overhaul. Avoid until audited revenue resumes.
Primary Thesis Risk
Terminal illiquidity coupled with operational revenue collapse and absent promoter backing.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Boston Bio Systems Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Boston Bio Systems Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of BOSTONBIO across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Conservative Debt Levels (D/E: 0.18)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Healthy Liquidity Position (Current Ratio: 2.07)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
8 factors identified
Below-Average Return on Equity (-10.34%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (0.11%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Profit Decline Concern (-32.65%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-100.00%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Weak Interest Coverage (0.02x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Low Promoter Commitment (2.14%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
Limited Institutional Interest (FII+DII: 1.70%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Boston Bio Systems Ltd vs Healthcare Service Provider Peers
Peer Comparison - Healthcare Service Provider
Compare Boston Bio Systems Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Boston Bio Systems LtdBoston Bio Syst...Selected✓ BOSTONBIO • 531458 | 0/100 | ₹7.49₹7 | ₹3.54₹3.54 | — — | -10.34%Poor -10.34% Poor | 0.11%Poor 0.11% Poor | 0.18Excellent 0.2 Excellent | — — | — — | 0.00% |
Dr. Lal Path Labs Ltd.Dr. Lal Path La... LALPATHLAB • 539524 | 57.7/100 | ₹1913.70₹1914 | ₹28908.91₹28908.91 | 53.35Average 53.3 Average | 21.57%Excellent 21.57% Excellent | 27.62%Excellent 27.62% Excellent | 0.00Excellent 0.0 Excellent | 11.60%Good 11.60% Good | 11.81%Good 11.81% Good | 0.81% |
Vijaya Diagnostic Centre LimitedVijaya Diagnost... VIJAYA • 543350 | 67.8/100 | ₹1483.40₹1483 | ₹14307.85₹14307.85 | 76.31Average 76.3 Average | 19.74%Good 19.74% Good | 21.32%Excellent 21.32% Excellent | 0.00Excellent 0.0 Excellent | — — | — — | 0.14% |
Metropolis Healthcare LimitedMetropolis Heal... METROPOLIS • 542650 | 57.9/100 | ₹566.70₹567 | ₹11858.49₹11858.49 | 58.81Average 58.8 Average | 13.36%Average 13.36% Average | 16.80%Good 16.80% Good | 0.01Excellent 0.0 Excellent | 0.74%Average 0.74% Average | 10.52%Good 10.52% Good | 0.35% |
Thyrocare Technologies LimitedThyrocare Techn... THYROCARE • 539871 | 46.7/100 | ₹596.05₹596 | ₹8420.27₹8420.27 | 47.76Average 47.8 Average | 28.80%Excellent 28.80% Excellent | 35.47%Excellent 35.47% Excellent | 0.00Excellent 0.0 Excellent | — — | 10.88%Good 10.88% Good | 1.76% |
Krsnaa Diagnostics LimitedKrsnaa Diagnost... KRSNAA • 543328 | 31.9/100 | ₹564.80₹565 | ₹1777.47₹1777.47 | 21.62Average 21.6 Average | 10.89%Average 10.89% Average | 13.05%Average 13.05% Average | 0.55Good 0.5 Good | — — | — — | 0.50% |
Suraksha Diagnostic LimitedSuraksha Diagno... SURAKSHA • 544293 | 56.2/100 | ₹317.85₹318 | ₹1359.30₹1359.30 | 37.97Average 38.0 Average | 14.11%Average 14.11% Average | 16.82%Good 16.82% Good | 0.01Excellent 0.0 Excellent | — — | — — | 0.00% |
One Global Service Provider LimitedOne Global Serv... ONEGLOBAL • 514330 | 82.2/100 | ₹546.20₹546 | ₹1178.25₹1178.25 | — — | — — | — — | — — | — — | — — | 0.00% |
3B Blackbio Dx Limited3B Blackbio Dx ... 3BBLACKBIO • 532067 | 60.3/100 | ₹1262.40₹1262 | ₹1079.13₹1079.13 | — — | — — | — — | — — | — — | — — | 0.31% |
Sastasundar Ventures LtdSastasundar Ven... SASTASUNDR • 533259 | 39/100 | ₹301.45₹301 | ₹1035.54₹1035.54 | 539.34Average 539.3 Average | 0.29%Poor 0.29% Poor | -0.05%Poor -0.05% Poor | 0.04Excellent 0.0 Excellent | 16.91%Excellent 16.91% Excellent | 19.09%Excellent 19.09% Excellent | 0.00% |
49.4/100 | ₹220.15₹220 | ₹600.78₹600.78 | 20.55Average 20.6 Average | 19.92%Good 19.92% Good | 23.27%Excellent 23.27% Excellent | 0.31Excellent 0.3 Excellent | — — | — — | 0.00% | |
Top Healthcare Service Provider Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Dr. Lal Path Labs Ltd. share price28908.91 Cr
- Vijaya Diagnostic Centre Limited share price14307.85 Cr
- Metropolis Healthcare Limited share price11858.49 Cr
- Thyrocare Technologies Limited share price8420.27 Cr
- Krsnaa Diagnostics Limited share price1777.47 Cr
Boston Bio Systems Ltd Quarterly Performance
Latest quarterly metrics for BOSTONBIO — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-100.00%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-32.65%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Boston Bio Systems Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for BOSTONBIO — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Boston Bio Systems Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Boston Bio Systems Ltd (BOSTONBIO) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Boston Bio Systems Ltd
About BOSTONBIO (Boston Bio Systems Ltd)
Boston Bio Systems Ltd is a distinguished healthcare service provider dedicated to advancing the field of diagnostics and personalized medicine. Since its inception, the company ha...s been committed to providing cutting-edge laboratory services and innovative solutions to healthcare professionals and patients alike. Specializing in complex diagnostic testing, Boston Bio Systems Ltd employs a team of highly skilled scientists, technicians, and medical professionals who utilize state-of-the-art equipment and advanced methodologies to deliver accurate and reliable results. Driven by a passion for improving patient outcomes, the company continuously strives to expand its test menu and incorporate the latest advancements in molecular biology, genomics, and proteomics. At the core of Boston Bio Systems Ltd's mission is a commitment to providing exceptional patient care and fostering strong collaborations with healthcare providers. The company operates a network of accredited laboratories equipped with sophisticated instrumentation, ensuring the highest standards of quality and precision. Boston Bio Systems Ltd offers a comprehensive range of diagnostic services, including molecular diagnostics, infectious disease testing, genetic screening, and cancer diagnostics. By providing timely and actionable insights, the company empowers physicians to make informed decisions and tailor treatment plans to meet the unique needs of each patient. Boston Bio Systems Ltd recognizes the importance of research and development in driving innovation and improving healthcare outcomes. The company actively invests in research initiatives aimed at developing new diagnostic tools and personalized medicine strategies. By collaborating with leading academic institutions and industry partners, Boston Bio Systems Ltd is at the forefront of scientific discovery and innovation. The company's commitment to excellence, scientific rigor, and patient-centric care has established it as a trusted partner for healthcare providers and patients seeking the highest quality diagnostic services.
Company Details
Key Leadership
BOSTONBIO Share Price: Frequently Asked Questions
What is the current share price of Boston Bio Systems Ltd?
Boston Bio Systems Ltd (BOSTONBIO) trades at ₹7.49 on NSE and BSE. Market cap ₹3.54 (Cr). Educational data only.
What is the P/E ratio of Boston Bio Systems Ltd?
Boston Bio Systems Ltd has a P/E of N/Ax vs industry average 42.23x.
What is the Bull Run score for Boston Bio Systems Ltd?
Boston Bio Systems Ltd has a Bull Run score of 0/100 based on 25+ financial parameters.
Does Boston Bio Systems Ltd pay dividends?
Boston Bio Systems Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Boston Bio Systems Ltd?
Boston Bio Systems Ltd has ROE of -10.34%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Boston Bio Systems Ltd?
Boston Bio Systems Ltd has debt-to-equity of 0.18.
Is Boston Bio Systems Ltd a good investment?
Bull Run gives Boston Bio Systems Ltd a score of 0/100. This is not investment advice — consult a SEBI-registered advisor.